A Phase 3 interventional study of Fluzoparib; Apatinib and Fluzoparib in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing fluzoparib in Ovarian Neoplasms — 13 open to participants now, 13 under way, 1 of them phase 3. fluzoparib · Ovarian Neoplasms.
Among the 22 studies testing fluzoparib in Ovarian Neoplasms, this one has the largest enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 5th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 22 studies testing fluzoparib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70 · Women only
Tongji Hospital · Sites in China
Ages 18+ · Women only · Healthy volunteers
Qilu Hospital of Shandong University · Sites in China
Ages 18+ · Women only
Qilu Hospital of Shandong University · Sites in China
Ages 18–75 · Women only
Fujian Cancer Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 690 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 70 across the 22 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 22 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 6 open now, 6 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one has the largest enrollment, is one of 3 that started in 2020, is one of 6 in phase 3, and was the 6th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Ovarian Neoplasms studies by the year they started, since 2015.
1 of the studies testing fluzoparib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07033819Cancer Institute and Hospital, Chinese Academy of Medical SciencesNeoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing fluzoparib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jiangsu HengRui Medicine Co., Ltd.’s 16 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, blinded, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Placebo, as maintenance treatment, in patients with Stage III or IV ovarian cancer. Patients must have completed first-line platinum based regimen with Complete Response (CR) or Partial Response (PR). The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 3 portion of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluzoparib+Apatinib
Drug: Fluzoparib; Apatinib
Fluzoparib
Drug: Fluzoparib
Placebo
Drug: Placebo
Drug pages: Fluzoparib · Apatinib
Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
Fluzoparib Orally twice daily
Placebo
(Safety Lead-in) Incidence of ≥3 grade TRAEs
Incidence of ≥3 grade treatment related adverse events
Time frame: up to 28 days after the last patient of the lead-in phase
(Phase 3) Progression free survival(PFS) in advanced ovarian cancer patients
Defined as progression free survival per RECIST 1.1 criteria according to BIRC criteria
Time frame: up to 4 years
AEs+SAEs
Adverse Events and Serious Adverse Events
Time frame: from the first drug administration to within 30 days for the last treatment dose
PFS by investigator's assessment
Progression-Free-Survival
Time frame: up to 4 years
OS
OS is the time interval from the start of treatment to death due to any reason or lost of follow-up
Time frame: up to 6 years
Patients reported outcome(PROs)assessed by EQ-5D-5L questionnaire
Comparison of the Quality of Life in study arms assessed by EQ-5D-5L questionnaire
Time frame: 48 months
Patients reported outcome(PROs)assessed by FOSI questionnaire
Comparison of the Quality of Life in study arms assessed by FOSI questionnaire
Time frame: 48 months
Time to progression on the next anticancer therapy (PFS2) From date of start of next anticancer therapy to date of first documented progression of date of death from any cause, whichever comes first.
From date of start of next anticancer therapy to date of first documented progression of date of death from any cause, whichever comes first.
Time frame: 4 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2020 (actual). Primary completion is estimated for Jun 2023, 36 months after the start.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 36 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluzoparib · Apatinib
Jiangsu HengRui Medicine Co., Ltd. →